Effects of first- and second-generation histamine-H1-receptor antagonists on the pentobarbital-induced loss of the righting reflex in streptozotocin-induced diabetic mice

Journal of Pharmacological Sciences

Volumn 97, Issue 2, 2005, Pages 266-272

  Kamei, Junzo ^a   Hirano, Shoko ^a   Miyata, Shigeo ^a   Saitoh, Akiyoshi ^a   Onodera, Kenji ^b  

^a HOSHI UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; Diabetes; Histamine H1 receptor antagonist; Loss of righting reflex; Pentobarbital

Indexed keywords

CETIRIZINE; DIPHENHYDRAMINE; EPINASTINE; EVANS BLUE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; PENTOBARBITAL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG PENETRATION; LOSS OF RIGHTING REFLEX; MALE; MOUSE; NONHUMAN; RIGHTING REFLEX; SEDATION; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

EID: 15744361996     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040832     Document Type: Article

References (35)

1. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003;31:312-318.
2. Nicholson AN, Pascoe PA, Turner C, Ganellin CR, Greengrass PM, Casy AF, et al. Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991;104:270-276.
3. Onodera K, Yamatodani A, Watanabe T, Wada H. Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Prog Neurobiol. 1994;42:685-702.
4. Emanuel MB. Histamine and the antiallergic antihistamines: a history of their discoveries. Clin Exp Allergy. 1999;29:1-11.
5. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target. 2001;9:223-228.
6. 1-antihistaminic agents in relation to their central sedative side-effects. Eur J Pharm Sci. 1994;2:373-384.
7. 3H-loratadine). Eur J Pharm Sci. 1996;4:307-319.
8. Horani MH, Mooradian AD. Effect of diabetes on the blood brain barrier. Curr Pharm Des. 2003;9:833-840.
9. Alex M, Baron EK, Goldenberg S, Blumaenthal HT. An autopsy study of cerebrovascular accident in diabetes mellitus. Circulation. 1962;25:663-673.
10. McCuskey PA, McCuskey RS. In vivo and electron microscopic study of the development of cerebral diabetic microangiography. Microcirc Endothelium Lymphatics. 1984;1:221-244.
11. Junker U, Jaggi C, Bestetti G, Rossi GL. Basement membrane of hypothalamus and cortex capillaries from normotensive and spontaneously hypertensive rats with streptozotocin-induced diabetes. Acta Neuropathol. 1985;65:202-208.
12. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R. Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes. 1987; 36:597-601.
13. Mayhan WG. Cerebral circulation during diabetes mellitus. Pharmacol Ther. 1993;57:377-391.
14. Stauber WT, Ong SH, McCuskey RS. Selective extravascular escape of albumin into the cerebral cortex of the diabetic rat. Diabetes. 1981;30:500-503.
15. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179-194.
16. Tamai I, Kido Y, Yamashita J, Sai Y, Tsuji A. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. J Drug Target. 2000;8:383-393.
17. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci. 2003;92:2082-2089.
18. van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, et al. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology. 2002;122:1842-1852.
19. Blomstrand C, Johansson B, Rosengren B. Blood-brain barrier lesions in acute hypertension in rabbits after unilateral X-ray exposure of brain. Acta Neuropathol. 1975;31:97-102.
20. Wolman M, Klatzo I, Chui E, Wilmes F, Nishimoto K, Fujiwara K, et al. Evaluation of the dye-protein tracers in pathophysiology of the blood-brain barrier. Acta Neuropathol. 1981;54:55-61.
21. Kozler P, Pokorny J. Altered blood-brain barrier permeability and its effect on the distribution of evans blue and sodium fluorescein in the rat brain applied by intracarotid injection. Physiol Res. 2003;52:607-614.
22. Tarui S, Yamada K, Hanafusa T. Animal models utilized in the research of diabetes mellitus-with special reference in insulitis-associated diabetes. Prog Clin Biol Res. 1987;229:211-223.
23. Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes. 1967;16:51-56.
24. Marley RJ, Miner LL, Wehner KM, Collins AC. Differential effects of central nervous system depressants in long-sleep and short-sleep mice. J Pharmacol Exp Ther. 1986;238:1028-1033.
25. Hendryk S, Jedrzefowska-szypulka H, Josko J, Jarzab B, Dohler KD. Influence of the corticotrophin releasing hormone (CRH) on the brain-blood barrier permeability in cerebral ischemia in rats. J Physiol Pharmacol. 2002;53:85-94.
26. Aoki T, Narita M, Ohnishi O, Mizuo K, Narita M, Yajima Y, et al. Disruption of the type 1 inositol 1,4,5-trisphosphate receptor gene suppresses the morphine-induced antinociception in the mouse. Neurosci Lett. 2003;350:69-72.
27. Guyot LL, Diaz FG, O'Regan MH, Song D, Phillis JW. The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex. Neurosurgery. 2001;48:385- 390;discussion 390-391.
28. Kamei J, Ohsawa M, Tsuji M, Takeda H, Matsumiya T. Modification of the effects of benzodiazepines on the exploratory behaviors of mice on a hole-board by diabetes. Jpn J Pharmacol. 2001;86:47-54.
29. Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy. 1999;29 Suppl 3:147-150.
30. 1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Find Exp Clin Pharmacol. 1995;17:64-69.
31. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74:70-76.
32. Sage JI, Van Uitert RL, Duffy TE. Early changes in blood brain barrier permeability to small molecules after transient cerebral ischemia. Stroke. 1984;15:46-50.
33. Mueller SM, Luft FC. The blood-brain barrier in renovascular hypertension. Stroke. 1982;13:229-234.
34. Dai J, Vrensen GF, Schlingemann RO. Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res. 2002;954:311-316.
35. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M. Terfenadine (Seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993;45:401-406.